ReviewTranslational lung cancer research2017
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.
Review in Translational lung cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- Lung Cancer in Never Smokers-An Underappreciated Public Health Burden.Health science reports · 2026Article
- Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases.Virchows Archiv : an international journal of pathology · 2026Article
- Review
- Splicing of HPV16 E6 promotes aggressive invasion in oropharyngeal cancer via endocytosis of E-cadherin.bioRxiv : the preprint server for biology · 2025Article
- Safety and feasibility of lapatinib for the treatment of a EGFR1/HER-2-positive advanced gastrointestinal stromal tumor in a cat.Brazilian journal of veterinary medicine · 2025Article
- Insights into post-marketing clinical validation of companion diagnostics with reference to the FDA, EMA, PMDA, and MFDS.Molecular therapy. Methods & clinical development · 2024Review
- Immunohistochemistry Screening of Different Tyrosine Kinase Receptors in Canine Solid Tumors-Part I: Proposal of a Receptor Panel to Predict Therapies.International journal of molecular sciences · 2024Article
- Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care.JCO oncology practice · 2024Article
- Comprehensive NGS profiling to enable detection ofFrontiers in oncology · 2023Article
- Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas.Translational lung cancer research · 2022Article
- Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Immunohistochemical and Electron Microscopy Evolution in the Diagnosis of Lung Cancer in Iraq.Archives of Razi Institute · 2022Article
- Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Review
- Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report.Frontiers in oncology · 2021Article
- Article
- Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.Virchows Archiv : an international journal of pathology · 2020Article
- Role of imaging biomarkers in mutation-driven non-small cell lung cancer.World journal of clinical oncology · 2020Review
- Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer.Translational lung cancer research · 2020Review
- Thymidylate synthase (TS) immunostaining in the diagnosis of the myoepithelial cells, basal cells, stratified epithelium cells, and associated tumors.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the era of targeted therapy, predictive biomarker testing has become increasingly important for non-small cell lung cancer. Of multiple predictive biomarker testing methods, immunohistochemistry (IHC) is widely available and technically less challenging, can provide clinically meaningful results with a rapid turn-around-time and is more cost efficient than molecular platforms. In fact, several IHC assays for predictive biomarkers have already been implemented in routine pathology practice. In this review, we will discuss: (I) the details of anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) IHC assays including the performance of multiple antibody clones, pros and cons of IHC platforms and various scoring systems to design an optimal algorithm for predictive biomarker testing; (II) issues associated with programmed death-ligand 1 (PD-L1) IHC assays; (III) appropriate pre-analytical tissue handling and selection of optimal tissue samples for predictive biomarker IHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.